CD177 and neoplasm: We screened tumor and immune cell mRNA expression of cell surface receptors and signaling molecules comparing high expression of these molecules (upper 25% percentile) versus remaining LGG patients for all the patients in the TCGA dataset (N = 513) using a univariate Cox proportional hazards model for patients treated with temozolomide (N = 259), radiation (N = 299), bevacizumab (N = 48), or lomustine (N = 39).